JPWO2020243745A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243745A5 JPWO2020243745A5 JP2022506342A JP2022506342A JPWO2020243745A5 JP WO2020243745 A5 JPWO2020243745 A5 JP WO2020243745A5 JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022506342 A JP2022506342 A JP 2022506342A JP WO2020243745 A5 JPWO2020243745 A5 JP WO2020243745A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tak
- administration
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 99
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 34
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 26
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000002246 antineoplastic agent Substances 0.000 claims description 21
- 229940127089 cytotoxic agent Drugs 0.000 claims description 21
- ZADWXQMNNVICKB-UHFFFAOYSA-N 6-ethyl-n-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide Chemical compound FC(F)(F)COC=1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(CC)=CC=2N(C)C=1C(=O)NC1CCN(C(=O)CO)CC1 ZADWXQMNNVICKB-UHFFFAOYSA-N 0.000 claims description 18
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 9
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
- 229960005277 gemcitabine Drugs 0.000 claims description 6
- 229960005386 ipilimumab Drugs 0.000 claims description 6
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 6
- 241000289669 Erinaceus europaeus Species 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- 229960004117 capecitabine Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229960000752 etoposide phosphate Drugs 0.000 claims description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 2
- 208000018212 fibroblastic neoplasm Diseases 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 230000001627 detrimental effect Effects 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 230000004044 response Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- POERAARDVFVDLO-QGZVFWFLSA-N 2-[5-[(2r)-4-(6-benzyl-4,5-dimethylpyridazin-3-yl)-2-methylpiperazin-1-yl]pyrazin-2-yl]propan-2-ol Chemical compound C([C@H]1C)N(C=2C(=C(C)C(CC=3C=CC=CC=3)=NN=2)C)CCN1C1=CN=C(C(C)(C)O)C=N1 POERAARDVFVDLO-QGZVFWFLSA-N 0.000 description 1
- SZBGQDXLNMELTB-UHFFFAOYSA-N 4-fluoro-n-methyl-n-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-2-(trifluoromethyl)benzamide Chemical compound C=1C=C(F)C=C(C(F)(F)F)C=1C(=O)N(C)C(CC1)CCN1C(C1=CC=CC=C11)=NN=C1C1=CC=NN1C SZBGQDXLNMELTB-UHFFFAOYSA-N 0.000 description 1
- -1 Gladegib Chemical compound 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- KLRRGBHZCJLIEL-UHFFFAOYSA-N n-[2-methyl-5-(methylaminomethyl)phenyl]-4-[(4-phenylquinazolin-2-yl)amino]benzamide Chemical compound CNCC1=CC=C(C)C(NC(=O)C=2C=CC(NC=3N=C4C=CC=CC4=C(C=4C=CC=CC=4)N=3)=CC=2)=C1 KLRRGBHZCJLIEL-UHFFFAOYSA-N 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- 229950000062 taladegib Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093180A JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853842P | 2019-05-29 | 2019-05-29 | |
| US62/853,842 | 2019-05-29 | ||
| PCT/US2020/070080 WO2020243745A1 (en) | 2019-05-29 | 2020-05-28 | Methods and uses for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093180A Division JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543021A JP2022543021A (ja) | 2022-10-07 |
| JPWO2020243745A5 true JPWO2020243745A5 (https=) | 2023-06-06 |
| JP2022543021A5 JP2022543021A5 (https=) | 2023-06-06 |
Family
ID=73553943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506342A Pending JP2022543021A (ja) | 2019-05-29 | 2020-05-28 | がんを処置する方法及び使用 |
| JP2025093180A Pending JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093180A Pending JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11911374B2 (https=) |
| EP (1) | EP3976036A4 (https=) |
| JP (2) | JP2022543021A (https=) |
| KR (1) | KR20220002745A (https=) |
| CN (2) | CN119326899A (https=) |
| AU (1) | AU2020283913A1 (https=) |
| BR (1) | BR112021026294A2 (https=) |
| CA (1) | CA3141072A1 (https=) |
| IL (1) | IL288591B1 (https=) |
| MX (1) | MX2021014686A (https=) |
| WO (1) | WO2020243745A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170326118A1 (en) * | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| MY150379A (en) * | 2008-02-26 | 2013-12-31 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| PL2470173T3 (pl) * | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP2012097032A (ja) * | 2010-11-02 | 2012-05-24 | Takeda Chem Ind Ltd | 併用医薬 |
| WO2014165644A2 (en) * | 2013-04-04 | 2014-10-09 | The General Hospital Corporation | Combination treatments with sonic hedgehog inhibitors |
| WO2015073691A1 (en) * | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| US10329304B2 (en) * | 2014-09-12 | 2019-06-25 | Vanderbilt University | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase |
| WO2016141084A1 (en) * | 2015-03-03 | 2016-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | Producing mesodermal cell types and methods of using the same |
| US11026889B2 (en) * | 2015-12-09 | 2021-06-08 | Board Of Regents, The University Of Texas System | Polymeric drug delivery systems for treatment of disease |
| CN108853507A (zh) * | 2017-05-11 | 2018-11-23 | 复旦大学 | 一种抗肿瘤的增效药物组合物及其制备方法和用途 |
| US20200368246A1 (en) * | 2017-11-17 | 2020-11-26 | Jaeyoung Yoon | Combination therapy targeting cancer associated with the hedgehog pathway |
-
2020
- 2020-05-28 WO PCT/US2020/070080 patent/WO2020243745A1/en not_active Ceased
- 2020-05-28 MX MX2021014686A patent/MX2021014686A/es unknown
- 2020-05-28 EP EP20814240.6A patent/EP3976036A4/en active Pending
- 2020-05-28 KR KR1020217042915A patent/KR20220002745A/ko active Pending
- 2020-05-28 CN CN202410646745.9A patent/CN119326899A/zh active Pending
- 2020-05-28 CA CA3141072A patent/CA3141072A1/en active Pending
- 2020-05-28 CN CN202080050914.2A patent/CN114126656A/zh active Pending
- 2020-05-28 JP JP2022506342A patent/JP2022543021A/ja active Pending
- 2020-05-28 AU AU2020283913A patent/AU2020283913A1/en not_active Abandoned
- 2020-05-28 BR BR112021026294A patent/BR112021026294A2/pt unknown
-
2021
- 2021-01-20 US US17/153,345 patent/US11911374B2/en active Active
- 2021-12-01 IL IL288591A patent/IL288591B1/en unknown
-
2025
- 2025-06-04 JP JP2025093180A patent/JP2025143272A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| US20220265592A1 (en) | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer | |
| KR20180048804A (ko) | 바리티닙 및 항암제를 포함하는 병용 요법 | |
| JP2021510725A5 (https=) | ||
| JP2016536352A5 (https=) | ||
| CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JPWO2020111018A5 (https=) | ||
| WO2009010287A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
| JP2019038796A5 (https=) | ||
| JP2017536408A5 (https=) | ||
| JP2016515586A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| JP2017503846A5 (https=) | ||
| JP2019038797A5 (https=) | ||
| Font et al. | Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| JP2021511344A5 (https=) | ||
| Afranie-Sakyi et al. | The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics | |
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| KR20180125967A (ko) | 암 치료용 pic 포함 조성물 | |
| Tanaka et al. | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| Thakur et al. | Different chemosensitization approaches for the effective management of HNSCC | |
| JPWO2020243745A5 (https=) |